Amplitude Vascular Systems (AVS), a medical device company focused on safely and effectively treating severely calcified arterial disease with its novel PULSE IVL™ platform, announced today that it has completed a Series B round of financing of $36M. The funding will support the U.S. peripheral commercial launch as well as U.S. coronary and carotid IDE trials for the company's Pulse Intravascular Lithotripsy™ (PIVL™) device.

Amplitude Vascular Systems (AVS) is a medical device company based in Boston, MA, focused on safely and effectively treating severely calcified arterial disease. The Pulse Intravascular Lithotripsy™ (PIVL™) System is an investigational device and not yet cleared for commercial distribution within or outside the United States.